In the next decade, we aim to become a Drug Discovery Powerhouse in which drug candidate compounds discovered and optimized by PeptiDream will be distributed to pharmaceutical companies and academic institutions globally, to be developed as cutting-edge therapeutics and diagnostics for a wide variety of diseases.

Since 2017, when I became CEO, my aspiration has been to build and grow PeptiDream into a leading global peptide discovery company, and to be a shining example of Japan biotech. Our innovative drug discovery platform system, PDPS (Peptide Discovery Platform System) is the cornerstone of PeptiDream’s business model that drives this aspiration. By utilizing the PDPS, I do not see any disease that cannot be therapeutically targeted by our macrocyclic peptides. The efficiency and speed of PeptiDream’s hit finding process creates sustainable value by delivering safe and innovative therapies to patients as early as possible.

2021 has been a remarkable year for us in accelerating our growth and innovation. Despite the challenging global effects of the pandemic, we have made exciting progress across our pipeline. Our R&D portfolio has spread across a variety of aspects, including radiopharmaceuticals, coronavirus infectious disease drugs, and nucleic acid drugs. News of breakthrough in oral administration of macrocyclic peptides brought tremendous impact to the science world. The establishment of our Sustainability Governance Committee has been effective in promoting discussion and decision making on ESG activities internally. We want to use limited resources even more efficiently, therefore we made the decision to completely switch to renewable energy within our operations from January 2022.

In the next decade, we aim to become a Drug Discovery Powerhouse in which drug candidate compounds discovered and optimized by PeptiDream will be distributed to pharmaceutical companies and academic institutions globally, to be developed as cutting-edge therapeutics and diagnostics for a wide variety of diseases. Towards this goal, it is my job to drive a fundamental transformation of the business to ensure sustainable value for PeptiDream. Our leadership team, founders, and employees understand that there is no significance for the presence of PeptiDream unless we continue to contribute to the sustainable growth of the society and humanity.

More broadly, as a collaboration company that has more than 120 research programs with partners worldwide, we believe understanding and addressing the needs of patients, colleagues, partners, shareholders, and communities is truly essential in creating a sustainable future for PeptiDream. I will continue to commit to delivering environmental and social impact and strive to integrate and embed these efforts within our organization and into our business.